| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Sonja Ständer | |
| Manuel Pereira | |||
| Claudia Zeidler | |||
| P2860 | cites work | Biological and Pharmacological Aspects of the NK1-Receptor | Q26784074 |
| New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms? | Q27692549 | ||
| The neurobiology of itch | Q28247676 | ||
| IL-31: a new link between T cells and pruritus in atopic skin inflammation | Q28295839 | ||
| Treatment of prurigo nodularis with topical capsaicin. | Q30981474 | ||
| Topical capsaicin (high concentration) for chronic neuropathic pain in adults. | Q34549233 | ||
| Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients | Q34552310 | ||
| Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. | Q34552408 | ||
| Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca2+ α2δ-1 subunit | Q35077880 | ||
| Treatment of pruritic diseases with topical calcineurin inhibitors. | Q35166799 | ||
| A central role for spinal dorsal horn neurons that express neurokinin-1 receptors in chronic itch | Q35761498 | ||
| Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome | Q35850819 | ||
| The effects of intrathecal and systemic gabapentin on spinal substance P release | Q35945726 | ||
| Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin | Q36811023 | ||
| Keratinocytes express cytokines and nerve growth factor in response to neuropeptide activation of the ERK1/2 and JNK MAPK transcription pathways | Q37237647 | ||
| A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. | Q37649820 | ||
| Antipruritic treatment with systemic μ-opioid receptor antagonists: a review | Q37749941 | ||
| Capsaicin in dermatologic disease | Q38213353 | ||
| The role of capsaicin in dermatology. | Q38221268 | ||
| Scratching behavior does not necessarily correlate with epidermal nerve fiber sprouting or inflammatory cell infiltration | Q38445295 | ||
| Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study | Q88647826 | ||
| Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU) | Q91087818 | ||
| NK-1 Receptor Antagonists and Pruritus: Review of Current Literature | Q92692621 | ||
| Novel drugs for the treatment of chronic pruritus | Q93065299 | ||
| Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis | Q93072432 | ||
| Dupilumab Treatment for Generalized Prurigo Nodularis | Q93072460 | ||
| EADV European Prurigo Project: Expert Consensus on the Definition, Classification and Terminology of Chronic Prurigo. | Q38600600 | ||
| Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience | Q38833912 | ||
| Gabapentin and pregabalin for the treatment of chronic pruritus | Q38840164 | ||
| Off-Label Uses of Topical Calcineurin Inhibitors | Q38844225 | ||
| Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord. | Q39661209 | ||
| Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). | Q39705730 | ||
| Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch | Q40058426 | ||
| The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch | Q40153067 | ||
| Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. | Q40585239 | ||
| The mechanism of action of cyclosporin A and FK506. | Q41114675 | ||
| Demonstration by S-100 protein staining of increased numbers of nerves in the papillary dermis of patients with prurigo nodularis | Q41142030 | ||
| Substance P activates Mas-related G protein-coupled receptors to induce itch | Q41285293 | ||
| Amitriptyline/Ketamine as therapy for neuropathic pruritus and pain secondary to herpes zoster | Q41478740 | ||
| Development and Evaluation of Topical Gabapentin Formulations. | Q42366834 | ||
| Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis | Q43086781 | ||
| Mechanisms of the sensory effects of tacrolimus on the skin | Q43123681 | ||
| Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies | Q44350825 | ||
| Janus kinase inhibitors display broad anti-itch properties: A possible link through the TRPV1 receptor. | Q44869758 | ||
| The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers | Q45109636 | ||
| Treatment of prurigo nodularis with pregabalin. | Q45248483 | ||
| Effects of tacrolimus ointment on the expression of substance P, nerve growth factor, and neurotrophin-3 in atopic dermatitis | Q46067172 | ||
| A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients | Q46343813 | ||
| Brachioradial Pruritus and Notalgia Paraesthetica: A Comparative Observational Study of Clinical Presentation and Morphological Pathologies. | Q47271046 | ||
| The role of topical anesthetics in the management of chronic pruritus | Q47382602 | ||
| Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis | Q47651588 | ||
| S2k Guidelines for the diagnosis and treatment of chronic pruritus - update - short version | Q47759075 | ||
| Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial | Q47805588 | ||
| The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, plac | Q47933206 | ||
| Topical amitriptyline-ketamine for the treatment of brachioradial pruritus | Q48088920 | ||
| Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial | Q48128267 | ||
| There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations | Q48333000 | ||
| Research progress of capsaicin responses to various pharmacological challenges. | Q49336561 | ||
| Chronic Prurigo of Nodular Type: A Review | Q50034306 | ||
| Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist. | Q50103131 | ||
| Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant | Q50275633 | ||
| Red ginseng inhibits scratching behavior associated with atopic dermatitis in experimental animal models. | Q50515988 | ||
| Olopatadine hydrochloride decreases tissue interleukin-31 levels in an atopic dermatitis mouse model. | Q50864976 | ||
| Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. | Q51637913 | ||
| PERINAL--a new no-touch spray to relieve the symptoms of pruritus ani. | Q51649280 | ||
| Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. | Q53082128 | ||
| Possible Antipruritic Mechanism of Cyclosporine A in Atopic Dermatitis. | Q53649536 | ||
| Novel TRPM8 agonist cooling compound against chronic itch: results from a randomized, double-blind, controlled, pilot study in dry skin. | Q53674324 | ||
| Aktuelles zur kutanen Neurobiologie von Pruritus | Q56984074 | ||
| Epidermal Nerve Fibers Modulate Keratinocyte Growth via Neuropeptide Signaling in an Innervated Skin Model | Q60678186 | ||
| Antipruritische Wirkung von Ciclosporin Microemulsion bei der Prurigo nodularis: Ergebnisse einer Fallserie | Q62073541 | ||
| Skin surface pH, moisture, and pruritus in haemodialysis patients | Q72684624 | ||
| Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems | Q74534991 | ||
| Effects of cyclosporine on pruritus and serum IL-31 levels in patients with atopic dermatitis | Q84502081 | ||
| P433 | issue | 4 | |
| P921 | main subject | chronic prurigo | Q60964900 |
| P304 | page(s) | 613-622 | |
| P577 | publication date | 2019-09-11 | |
| P1433 | published in | Dermatology and therapy | Q27724445 |
| P1476 | title | The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo | |
| P478 | volume | 9 |
Search more.